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Abstract 
Objectives: To describe the epidemiology of Ebstein’s anomaly in Europe and its 
association with maternal health and medication exposure during pregnancy.  
Design: Descriptive epidemiologic analysis of population-based data  
Setting: 15 EUROCAT Congenital Anomaly Registries in 12 European countries: population 
5.6 million births 1982-2011.  
Participants: Cases included livebirths, fetal deaths from 20 weeks gestation, and 
terminations of pregnancy for fetal anomaly.  
Main outcome measures: Total prevalence per 10,000 births. Odds ratios for exposure to 
maternal illnesses / medications in the first trimester of pregnancy were calculated by 
comparing Ebstein’s anomaly cases to cardiac and non-cardiac malformed controls, 
excluding genetic syndromes; adjusted for time period and country. 
Results: 264 Ebstein’s anomaly cases were recorded; 81% were livebirths, 2% of which 
were diagnosed after the first year of life. 54% of cases Ebstein’s anomaly or a co-existing 
congenital anomaly was prenatally diagnosed. Total Prevalence rose over time from 0.29 
(95%CI 0.20-0.41 to 0.48 (95%CI 0.40-0.57) (p<0.01). Nine cases were exposed to maternal 
mental health conditions/medications (adjOR 2.64, 95%CI 1.33-5.21) compared to cardiac 
controls. Cases were more likely to be exposed to maternal beta thalassemia (adjOR 10.5, 
95%CI 3.13-35.3, n=3) and haemorrhage in early pregnancy (adjOR 1.77, 95%CI 0.93-3.38, 
n=11) compared to cardiac controls. 
Conclusions: The increasing prevalence of Ebstein’s anomaly may be related to better and 
earlier diagnosis. Our data suggest that Ebstein’s anomaly is associated with maternal 
mental health problems generally rather than lithium or benzodiazepines specifically, 
therefore changing or stopping medications may not be preventative. We find new 
associations requiring confirmation. 
Introduction 
Ebstein’s anomaly is a rare, congenital cardiac anomaly of the tricuspid valve and right 
ventricle first described by Wilhelm Ebstein in 1866 (1). Cases were traditionally diagnosed 
at all ages, with the worst outcomes for neonates who need interventions for cyanotic 
disease (2). Diagnosis is increasingly happening prenatally; as this anomaly develops 
throughout fetal life, it can occur in cases who had an apparently structurally normal heart on 
earlier ultrasonic scan (3). High rates of spontaneous abortion throughout pregnancy have 
been reported (4).  
An association between Ebstein’s anomaly and maternal lithium exposure was first reported 
in the 1970s (5) and led to recommendations still in place today to switch to other 
antipsychotics in pregnancy where possible (6), but this association has been disputed in 
more recent literature (7). Associations have also been found with other exposures, including 
benzodiazepines (8), antihypertensives (9), valproic acid (10), marijuana (11) and organic 
solvents (11).  
A previous study of congenital anomalies associated with selective serotonin reuptake 
inhibitors use, using some of the same data, found an association with Ebstein’s anomaly 
(12).  The purpose of the present study was to test the robustness of this finding by using a 
larger population and different controls and set it in the context of other mental health-related 
exposures, and to ascertain other aspects of the epidemiology of Ebstein’s anomaly.. 
Methods 
European Surveillance of Congenital Anomalies (EUROCAT) is a network of population-
based registries of congenital anomaly in 21 countries of Europe (13). The methods of 
registry case ascertainment are fully described elsewhere (14). The central database 
includes standardised data on live born congenital anomaly cases, stillborn cases and fetal 
deaths after 20 weeks’ gestation, and prenatally diagnosed cases resulting in termination of 
pregnancy for fetal anomaly. One week survival is also ascertained for liveborn cases (15). 
All registries record diagnoses made prenatally or at birth, most registries record diagnoses 
made up to one year of life, and some registries record diagnoses made in later childhood 
(14).  
The 15 EUROCAT congenital anomaly registries in 12 countries (Table 1) which agreed to 
take part collect data on maternal illness before and during pregnancy and on maternal drug 
exposure in the first trimester of pregnancy. Most sources of exposure data were prospective 
to outcome, except in one centre where exposure data are ascertained exclusively by 
interviewing mothers and clinicians after the congenital anomaly has been diagnosed. Three 
other registries use maternal interviews to confirm their data (Table 1). 
Other variables used in this study were syndrome and malformation diagnoses (coded to 
International Classification of Diseases versions 9 and 10 with British Paediatric Association 
extension), family history of congenital anomaly, maternal age and parity, and gestational or 
postnatal age at diagnosis (15). Denominators including live and stillbirths are available by 
registry and year.  
The total study population was 5,644,312 births covering the years 1982 to 2011. (Table1: 
Online appendix Table1A). 145,084 babies/fetuses with major congenital anomaly were 
registered of which 264 were diagnosed as having Ebstein’s anomaly (Table 1). All cases 
were included in the descriptive prevalence study. A case-malformed control study was also 
carried out comparing cases of Ebstein’s anomaly with controls with cardiac and non-cardiac 
major malformations from the database separately. Excluded from both cases and controls 
were cases with chromosomal syndromes (11 cases and 20,316 controls), genetic 
syndromes (2 cases, 2,898 controls), skeletal dysplasia (no cases and 649 controls) and 
teratogenic syndromes (1 case and 677 controls). Controls with only hip dysplasia (n=5,698 
associated with higher gestational age at birth) were also excluded leaving 250 cases and 
35,904 controls with cardiac and 78,678 with non-cardiac anomalies for the analysis of 
maternal and family exposures (See Figure 1A: online supplement for details of exclusions). 
Analyses of maternal medication involved 173 EA cases and 26,184 cardiac and 51,024 
non-cardiac controls from a population of 3,662,154 births since 1995 (See Figure 1A: online 
supplement) as medication data were not available for all years (Table1). International 
Classification of Diseases 9/10 codes for maternal diseases/conditions and Anatomical 
Therapeutic Chemical codes for medication corresponding to the categories analysed are 
given in online supplement Table 2A. Maternal diabetes included both pregestational and 
gestational diabetes due to the potential for undiagnosed pregestational diabetes among 
those with gestational diabetes (16,17) and the possibility of late development of Ebstein’s 
anomaly (3) 
 
Statistical analysis  
Total Prevalence of Ebstein’s anomaly cases per 10,000 births was calculated as: 
Number of Ebstein’s anomaly cases (livebirths +fetal deaths+ terminations of 
pregnancy for fetal anomaly) *10,000 
Total number of babies (livebirths+stillbirths) in the population 
 
Prevalence, and proportions by prenatal diagnosis and pregnancy outcome, were calculated 
for three time periods (Figure 1) and for each country for the years 1992-2011 (Figure 1) 
when prevalence had stabilised in time. 
Odds ratios (OR), with 95% confidence intervals, estimated using logistic regression to 
analyse risk factors are only presented where there are at least 3 exposed Ebstein’s 
anomaly cases. ORs were adjusted for year of birth, with the data divided into the time 
periods 1982-1991, 1992-2001 and 2002-2011 and country (pooling data from registries 
within the same country: Table 1). For analysis of maternal age, maternal age was divided 
into 3 groups: <25, 25-34 and >34. All cases exposed to maternal diabetes, even if it 
occurred later in pregnancy, were excluded from the mental health analysis and vice versa 
to avoid confounding. 
Prior hypotheses for investigation were lithium selective serotonin reuptake inhibitors, other 
mental health medications, maternal depression and other mental health conditions and 
maternal diabetes. For other exposures, an exploratory analysis first examined the data to 
find which maternal diseases/conditions and medication exposures were recorded for at 
least three Ebstein’s anomaly cases, and these exposures were then subject to statistical 
analysis.  
 
Results 
Associated syndromes, malformations and family history 
Of the 264 Ebstein’s anomaly cases, 11 (4.17%) had chromosomal anomalies (Table 3A, 
online supplement), less than the 11.9% proportion of chromosomal anomalies among non-
Ebstein cardiac anomaly cases. Two cases (0.76%) were diagnosed with other genetic 
syndromes (Table 3A) compared with 2.35% of other cardiac anomalies. Few cases had any 
recorded family history (Table 4A, online supplement). Of the 250 non-syndromic Ebstein’s 
anomaly cases, 86 had other cardiac anomalies (34%) including 23 reported as having an 
ASD only. Twenty EA cases had other right ventricular outflow tract obstruction anomalies 
(5) - pulmonary valve atresia or stenoses. Nine cases had coarctation of the aorta.   
Ebstein’s anomaly cases were less likely to be associated with non-cardiac anomalies 
(8.8%, 22 cases) than other cardiac anomaly cases (17.6%) (Table 5A, online supplement).  
No specific anomaly was associated with Ebstein’s anomaly in more than 2 cases. 
Prevalence, age at diagnosis, pregnancy outcome and sex ratio  
The average total prevalence of Ebstein’s anomaly was 0.47 (95%CI 0.41-0.53) per 10,000 
births ranging from 0.27 (95%CI 0.20-0.36) in Italy to 0.95 (95%CI 0.53-1.72) in Malta (Table 
1). The total prevalence rose significantly from 0.29 (95%CI 0.20-0.41) in the decade 1982-
1991 to 0.55 (95%CI 0.46-0.67) in the decade 1992-2001 (trend p<0.01) remaining high at 
0.48 (95%CI 0.40-0.57) in the decade 2002-2011 (Figure 1; online appendix Table 6A). The 
decrease in prevalence between the second and third decades was not statistically 
significant.   
The prevalence of prenatally diagnosed cases (where either Ebstein’s anomaly or an 
associated anomaly were prenatally diagnosed) per 10,000 births rose over time and varied 
between countries (Figure 2). The proportion of all cases which were prenatally diagnosed 
rose over time to 54% in the last decade (Figure 2) with 57% of all the isolated Ebstein’s 
anomaly cases prenatally diagnosed in that decade. The proportion of terminations of 
pregnancy for fetal anomaly rose to 16.7% in the last decade (Figure 3). The prevalence and 
proportion of terminations of pregnancy for fetal anomaly varied between countries (Figure 
3). Termination of pregnancy for fetal anomaly is illegal in both Malta and Ireland. Of the 97 
prenatally diagnosed, non-syndromic cases where gestational age at diagnosis was known, 
85 (87.6%) were diagnosed at or after 20 weeks’ gestation and 44 (45.4%) after 24 weeks 
gestation. Overall, 16.5% of postnatally diagnosed liveborn cases were diagnosed after the 
first week of life, not varying substantially between decades.  Only 5 cases (2%) were 
diagnosed after 1 year of life.  
16 Ebstein’s anomaly cases were stillbirths, 0.03 (95%CI 0.02-0.05) per 10,000 births, 
Figure 3). 22 EA cases were known to be early neonatal deaths, a rate of 0.04 (95%CI 0.03-
0.06) per 10,000 births, Figure 3).  
50.8% of 250 non-syndromic cases were male (excluding 3 cases of unknown sex).  
Case-malformed control analysis of risk factors 
Neither the odds of older or younger maternal age was significantly different from controls 
(Table 2) but the odds of being a firstborn child, adjusted for maternal age, were significantly 
lower than that of  all controls  (Table 2). Cases were non-significantly more likely to have 
been from multiple births than non-cardiac controls (Table 2).There was one pair of co-twins 
concordant for Ebstein’s anomaly, a monozygotic pair with twin to twin transfusion. Ebstein’s 
anomaly were non-significantly less likely to have had assisted reproduction than either 
control group (Table 2). 
Nine cases were exposed to mental illness and/or an antidepressant or a psycholeptic 
medication or both (adjOR 2.80, 95%CI 1.42-5.51, non-cardiac controls, Table 2). The odds 
ratio was similar when compared to cardiac controls (adjOR 2.64, 95%CI 1.33-5.21) 
indicating that this effect was specific to Ebstein’s anomaly (Table 2). High odds ratios were 
found for all the subcategories analysed - psycholeptic medications, antidepressants, 
selective serotonin reuptake inhibitors, diagnosis of anxiety, diagnosis of depression (Table 
2).  No Ebstein’s anomaly case was exposed to lithium, but 5 cardiac and 8 non-cardiac 
controls were lithium-exposed. Further details of exposures of Ebstein’s anomaly cases are 
given in the footnote of Table 2.  Three of the five cases of selective serotonin reuptake 
inhibitors exposure we found were also in our previous study (12) which covered an 
overlapping population (28% of the population of this paper). 
 
Ebstein’s anomaly was non-significantly associated with diabetes compared to non-cardiac 
controls and was as likely to be associated with diabetes as other cardiac anomalies (Table 
2). Cases were not more likely than controls to have been exposed to non-psychotropic / 
non-diabetic medications (0.87, 95%CI 0.54-1.39, Table 2). 
Cases were more likely to have been exposed to maternal beta thalassemia (adjOR 12.9 
(95%CI 3.85-43.0)) based on only 3 cases (Table 2).  Haemorrhage in early pregnancy/ 
threatened abortion was associated with an elevated OR (Table 2).   
Discussion 
Ebstein’s Anomaly and mental health conditions and their medication. 
We found that the risk of Ebstein’s anomaly rises nearly threefold where the mother is 
reported to have mental health conditions with medication. Our data suggest that it is not 
lithium or benzodiazepines specifically which are associated with Ebstein’s anomaly as had 
been previously thought (5,7,8).), or SSRIs specifically as we and others had previously 
shown (12) but that medicated mental illness in general is a risk factor.  We had no data on 
unmedicated mental illness, and cannot effectively distinguish medication from indication, 
although the lack of a specific medication effect points to the possibility of the risk being 
associated with the underlying health condition. Our analyses suggest that switching away 
from specific medications such as lithium does not protect the fetus. Our data also robustly 
suggest that these exposures are much more strongly associated with Ebstein’s anomaly 
than cardiac anomalies in general. Recent literature has explored the relationships between 
congenital cardiac anomalies and both psychiatric conditions and the complex combinations 
of medications used to control them; other exposures of sufferers may also influence risk or 
act as confounders (18). We had no systematic data on factors such as smoking, alcohol, or 
recreational drugs. We excluded those with diabetes from the mental health analyses to 
avoid confounding due to the association of diabetes and depression(19). 
Ebstein’s anomaly and other maternal illnesses. 
Pregestational diabetes is known to be associated with cardiac and other congenital 
anomalies (17,20) but has not been specifically investigated with regard to Ebstein’s 
anomaly. Ebstein’s anomaly, although it can be detected as early as 14 weeks’ gestation, is 
known to occasionally develop later in pregnancy (3). It has been hypothesized that as 
women diagnosed with gestational diabetes are more likely to be overweight or obese they 
may have suffered from undiagnosed type 2 diabetes before pregnancy (17), so we grouped 
gestational and pregestational disease together, finding a weak association between 
Ebstein’s anomaly and diabetes when compared with non-cardiac controls. This odds ratio is 
likely to be underestimated due to the inclusion in the control group of other malformations 
associated with diabetes (17,20). The lack of elevated odds compared to cardiac controls 
suggests that Ebstein’s anomaly has a similar association to diabetes as cardiac anomalies 
in general (17,20).  Although an association was found between right ventricular outflow tract 
anomalies and pregestational diabetes in one study, none of the exposed cases in that study 
had Ebstein’s anomaly (17), and 5 exposed cases were not available for analysis in another 
(20), therefore we conclude that, although diabetes is an important risk factor for congenital 
cardiac anomalies in general, it is not specifically associated with Ebstein’s anomaly. 
We were not able to confirm an association between maternal febrile illness, especially 
genitourinary tract infections, and right ventricular outflow tract obstructions (21) as being 
specific to Ebstein’s anomaly.  
Our finding that there is a strong association with beta-thalassemia is new, but it is based on 
only 3 cases and not hypothesis driven and thus needs confirmation in an independent 
dataset.  
Epidemiology of Ebstein’s Anomaly 
We estimate a prevalence of Ebstein’s anomaly in Europe of 0.47 cases per 10,000 births 
which is consistent with those in other populations - 0.39 per 10,000 births in Hawaii (1986-
1999) (22), 0.52 per 10,000 births in Baltimore (1981-1989) (8), 0.6 per 10,000 in Atlanta 
(1992-2005) (23) and 0.72 per 10,000 births in Texas (1999-2005) (24). Our cases were 
drawn from a population of 5.6 million births, more than twice the population of the next 
largest of these studies (24). The highest European prevalence in our study was found in 
Malta where the estimate is based on small numbers, but where prevalence of congenital 
cardiac anomalies is known to be high relative to the rest of Europe (25,26).  
The significant increase in prevalence which we found from the 1980s to the 1990s may be 
due in part to the increase in prenatal diagnosis and in terminations of pregnancy for fetal 
anomaly as a proportion of cases are lost spontaneously in late pregnancy (3,4). Prenatal 
and early diagnosis may also lead to better ascertainment of cases which might have been 
diagnosed later in life in the first study decade, or missed in late fetal and neonatal deaths.  
More than half of cases were prenatally diagnosed since the 1990s, mostly after 20 weeks 
gestation, and often diagnosed after 24 weeks gestation. There is evidence that the majority 
of cases can be diagnosed by ultrasound as early as 14 weeks gestation (3), and although 
infrequently Ebstein may develop after 20 weeks {Zimmer}, diagnosis in late pregnancy may  
reflect the timing of routine congenital anomaly scans throughout Europe (27). 
Our finding that Ebstein’s anomaly is less likely to be part of chromosomal syndromes than 
other cardiac anomalies is consistent with other studies (8). Less than 1% of our cases were 
known to have a monogenic or microdeletion syndrome, but this may be partly because 
specific genetic testing has been infrequently carried out; two cases (both terminations of 
pregnancy for fetal anomaly) are reported to have thymic agenesis which could indicate an 
undiagnosed genetic syndrome.  In genetic studies of the disease, microdeletions have been 
found (28) . Although there are reports of familial associations of the disease, these are rare 
(29) and first degree relatives of Ebstein’s anomaly cases are more likely to have other 
congenital heart defects (30).  
The association of Ebstein’s anomaly with multiple births is inconsistent in the literature 
(23,24) and we found only a weak association. It is interesting that, like Correa-Villasenor 
and co-workers (8) we found a twin pair concordant for Ebstein’s anomaly.  Monozygotic 
twins are usually discordant for CHD, with the lesion possibly occurring either as a result of a 
disturbance in laterality in one twin during separation or as a result of imbalance in placental 
blood flow (31). Although our twins did have a twin to twin transfusion it is difficult to imagine 
that such a transfusion caused an identical lesion in both donor and recipient twin; more 
likely there was a genetic disposition, a teratogenic cause or a combination of both. Correa-
Villasenor’s twins were reportedly dizygotic and had an older sibling also diagnosed with 
Ebstein’s anomaly. One of the other twins in our data is reported to have had a twin to twin 
transfusion, but in that case the co-twin was not reported as having a congenital anomaly. 
One could hypothesise that the higher rate of haemorrhage in early pregnancy/ threatened 
abortion in cases than controls, although not reaching statistical significance, may indicate 
the early loss of co-twins (32).  
Our finding that Ebstein’s anomaly cases are less likely to be firstborn children support the 
findings of Correa-Villasenor and co-workers (8), but our data do not support their findings of 
an association with older maternal age or assisted reproductive therapy.  
Strengths and limitations of this study 
The strengths of our study are the large population with standardised data on congenital 
anomaly diagnoses, the inclusion of all pregnancy outcomes (livebirths, stillbirths and 
terminations of pregnancy), and the prospective nature of most medication recording (blind 
to anomaly status). The main limitation of our data was probable under ascertainment of 
exposure status across a range of variables, although this would have been unbiased in the 
case-malformed control design. We used controls which have the same probability of 
exposure and of ascertainment of that exposure as the cases (33,33,34), and could 
therefore judge the specificity of association with Ebstein’s anomaly in comparison both with 
non-cardiac and other cardiac anomalies. However, the disadvantage of the case-malformed 
control design is that any exposure which is related to the controls will lead to an 
underestimate of the OR for Ebstein’s anomaly – the so called “teratogen non-specificity bias 
(35) - for example, this could have diluted the OR for diabetes or selective serotonin 
reuptake inhibitors use where other anomalies are also implicated (12,17,20)). We analysed 
multiple exposures in our exploratory analyses, and the results should be interpreted taking 
into account the possibility of chance associations. Since Ebstein’s anomaly may sometimes 
develop later than first trimester (3) later medication exposures may be aetiologically 
significant, but EUROCAT data includes only first trimester exposures.  
Conclusions 
Ebstein’s anomaly is diagnosed in approximately one in 21,000 babies in Europe. Ebstein’s 
anomaly is associated with a range of maternal health conditions and related medications 
and our data support and broaden previous literature. There is a new signal in our data for 
an association between Ebstein’s anomaly and maternal beta-thalassemia which requires 
further confirmation.   
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Table 1: Study population (births) by country and year.   
Country Years 
included in 
the study 
Years 
included in 
medication  
analysis 
Study 
population 
1982-2011: 
total births 
EA: number of cases and 
prevalence per 10,0000 births 
(with 95% confidence 
intervals) 1982-2011 
Denmark (Odense)M 1982-2011 1995-2011 159,595 10 0.63 (0.34-1.16) 
France (Paris) M 1982-1011 2001-2011 994,614 61 0.61 (0.48-0.79) 
Netherlands(Northern) MIP 1982-2011 1995-2001 506,121 26 0.51 (0.35-0.75) 
Switzerland (Vaud) M 1989-2011 1997-2001 174,162 13 0.75 (0.43-1.29) 
Malta M 1986-2010 1996-2011 115,713 11 0.95 (0.53-1.72) 
Belgium (Antwerp) M 1990-2011 1997-2011 341,573 12 0.35 (0.20-0.62) 
Germany (Saxony) MI 1987-2011 2000-2011 352,844 12 0.34 (0.19-0.60) 
Ukraine M 2005-2011 2005-2011 208,772 13 0.62 (0.36-1.07) 
Ireland* M 1996-2011 1996-2011 232,388 11 0.47 (0.26-0.85) 
Italy* MIX 1982-2011 1995-2011 1,496,807 40 0.27 (0.20-0.36) 
UK (Wales) M 1998-2011 1998-2011 466,301 32 0.69 (0.49-0.97) 
Spain* M 1990-2010 1995-2011 595,422 23 0.39 (0.26-0.58) 
Total 1982-2011 1995-2011 5,644,312 264 0.47 (0.41-0.53) 
*Ireland = Cork and Kerry 1996-2010 & SE Ireland 1997-2010 
* Italy = Tuscany 1982-2011& Emilia Romagna 1982-2011 
*Spain = Basque Country 1990-2010 & Valencia 2007-2010 
M Medication ascertainment from maternal medical/midwifery notes 
I Information on medication exposure taken from or confirmed through maternal interviews 
P Information available on maternal prescriptions 
x Tuscany has information from maternal interviews only, Emilia Romagna from both interviews and notes. 
 
Table 2: Ebstein’s Anomaly: Number, crude odds ratios (OR) and odds ratios adjusted 
for country and time (adjOR) for maternal characteristics and medication exposures 
compared to non-cardiac malformed control cases. 
 
m Analysis restricted to years with medication data available (Table 1) 
*Cases and controls where the total number of previous pregnancies was unknown were excluded (47 (18.8%) cases 16,958 (21.6%) 
controls. OR adjusted for country and time were also adjusted for maternal age. 
** 1992-2011only 
***There were no cases with recorded exposure to maternal mental illness who were not exposed to psycholeptic or antidepressant 
medications. 3 of the 9 cases with medications had no diagnosis recorded, including one who took an antipsychotic.  2 cases exposed  to 
psycholeptics, both exposed to a benzodiazepine derivative (anxiolytics), were also exposed to a Selective Serotonin Reuptake Inhibitor 
(SSRI). There were 2 cases exposed to SSRIs only. One mother, who took both a benzodiazepine derivatives and an SSRI, was also using 
beta-blockers and drinking more than 5 units of alcohol per day. The other 8 had no relevant medical history, were not known to have used 
assisted reproductive therapies (ART) and all were singleton births.  
XP Excluding cases and controls exposed to mental health issues (0 cases, 18 cardiac, 40 non-cardiac controls). Two pregestational, three 
gestational. 
XD Excluding cases and controls exposed to diabetes (0 cases, 18 cardiac, 40 non-cardiac controls)   
 
Exposure  Non-cardiac controls Cardiac controls 
 Cases 
exposed 
Controls 
exposed 
OR (95%CI) Adjusted for country 
and time 
Controls 
exposed 
OR (95%CI) Adjusted for country 
and time 
Maternal reproductive history         
Firstborn* 69 24,660 0.72 (0.54-0.96) 0.70 (0.52-0.95) 11,255 0.76 (0.57-1.02) 0.74 (0.56-0.99) 
Maternal age <25 52 15,165 1.10 (0.80-1.51) 1.14 (0.82-1.58) 6,388 1.18 (0.86-1.62) 1.24 (0.89-1.73) 
Maternal age >34 45 14,078 1.02 (0.73-1.42) 1.03 (0.74-1.45) 6,932 0.94 (0.67-1.32) 0.95 ( 0.68-1.33) 
ART ** 4 1,862 0.65 (0.24-1.75) 0.61 (0.23-1.66) 885 0.65 (0.24-1.74) 0.58 (0.22-1.58) 
Multiple birth 14 3,084 1.51 (0.88-2.59) 1.48(0.86-2.55) 1,746 1.18 (0.69-2.03) 1.17 (0.68-2.02) 
        
Mental Health  XD        
Mental illness or medication XD***    9 962 3.04(1.56-5.94) 2.80 (1.42-5.51) 497 2.65 (1.35-5.18) 2.64 (1.33-5.21) 
Depression XD   4 330 3.89 (1.44-10.5) 3.52 (1.19-8.91) 203 2.84 (1.05-7.71) 2.70 (0.98-7.43) 
Anxiety XD 3 56 17.2(5.34-55.3) 15.4(4.72-49.9) 34 12.7 (3.89-41.8) 13.8 (4.15-45.8) 
Psycholeptic (N05) m  XD 4 266 4.56 (1.68-12.4) 4.50 (1.64-12.3) 122 5.02 (1.84-13.8) 4.95 (1.79-13.7) 
Antidepressants (N06A) m  XD 7 359  6.02 (2.80-12.9) 6.00 (2.76-13.0) 186 5.86 (2.71-12.7) 6.04 (2.75-13.2) 
SSRIs (N06AB)  m XD 4 234 5.19 (1.91-14.1) 5.24 (1.91-14.4) 116 5.29 (1.93-14.5) 5.35 (1.93-14.9) 
SSRI excluding other 
antidepressants m XD 
4 234 5.27 (1.94-14.3) 5.39 (1.96-14.8) 116 5.37 (1.96-14.7) 5.49 (1.97-15.3) 
Antidepressants excluding 
Psycholeptics m  XD 
5 303 5.13 (2.09-12.6) 5.32 (2.14-13.2) 159 4.97 (2.01-12.3) 5.22 (2.08-13.1) 
Mental illness excluding 
psycholeptics  m XD 
5 601 2.57 (1.05-6.29) 2.50 (1.01-6.16) 341 2.29 (0.93-5.61) 2.14 (0.87-5.29) 
        
Non mental health / non-
diabetic medications m 
 
23 7,923 0.88 (0.57-1.37) 0.87 (0.54-1.40) 3,937 0.90 (0.58-1.40) 0.89 (0.56-1.43) 
Disease/condition        
Diabetes XP 6 1,285 1.52 (0.67-3.42) 1.51 (0.67-3.40) 1,063 0.82 (0.37-1.86) 0.87 (0.38-1.96) 
Beta thalassemia  XP XD 3 114 8.65 (2.73-27.4) 12.9 (3.85-43.0) 65 6.81 (2.13-21.8) 10.5 (3.13-35.3) 
Haemorrhage in early pregnancy  
XP XD 
11 1,602 2.29 (1.25-4.21) 1.77 (0.92-3.38) 771 2.14 (1.16-3.93) 1.77 (0.93-3.38) 
        
Maternal infection        
Genitourinary infection  XP XD 3 799 1.22 (0.39-3.83) 1.02(0.32-3.24) 394 1.11 (0.36-3.49) 1.03 (0.33-3.28) 
Antibiotics (J01) m  XP XD 6 1,277 1.47 (0.65-3.33) 1.68 (0.73-3.87) 632 1.50 (0.66-3.40) 1.80 (0.78-4.15) 
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Table 1A: Study population (births) by country and year.   
Country Years 
included  
1982-1991 1992-2001 2002-2011 Total births 
in study 
years  1982-
2011 
Years 
included in 
medication  
analysis 
Total births 
in medication 
study years 
1995-2011   
Denmark (Odense) 1982-2011 49,475 5,7936 52,184 159,595 1995-2011 92,211 
France (Paris)  1982-1011 365,807 361,464 267,343 994,614 2001-2011 293,767 
Netherlands(Northern)  1982-2011 124,583 196,761 184,777 506,121 1995-2001 323,728 
Switzerland  (Vaud)  1989-2011 23,120 76,232 74,810 174,162 1997-2001 112,156 
Malta  1986-2010 32,491 47,238 35,984 115,713 1996-2011 63,051 
Belgium (Antwerp)  1990-2011 8,428 135,969 197,176 341,573 1997-2011 286,751 
Germany (Saxony)  1987-2011 72,877 106,958 173,009 352,844 2000-2011 209,956 
Ukraine  2005-2011   208,772 208,772 2005-2011 208,772 
Ireland*  1996-2011  74,817 157,571 232,388 1996-2011 232,388 
Italy*  1982-2011 315,353 507,186 674,268 1,496,807 1995-2011 1,031,189 
UK (Wales)  1998-2011  128,106 338195 466,301 1998-2011 466,301 
Spain*  1990-2010 32,729 163,572 399,121 595,422 1995-2011 341,884 
Total 1982-2011 1,024,863 1,856,239 2,763,210 5,644,312 1995-2011 3,662,154 
Ireland = Cork and Kerry 1996-2010 & SE Ireland 1997-2010 
  * Italy = Tuscany  1982-2011 & Emilia Romagna 1982-2011 
*Spain = Basque Country 1990-2010 & Valencia 2007-2010 
 
 
Table 2A: ICD9 /10 codes and Drug (ACT) codes used in the analysis 
Disease / Condition / Anomaly ICD10 ICD9 ACT 
Ebstein’s anomaly Q22.5 746.2  
    
Beta-thalassemia D561 282.4  
Haemorrhage in pregnancy O20* 640*  
Genitourinary infection in 
pregnancy 
O23* 646.6  
Depression F32/33 311*  
Anxiety F41* 300*  
Mental illness F* 29*/30*/31*  
Diabetes E10*/11*/12*/13*/14* 249*250*  
Gestational Diabetes 0244/9 6480/8  
Antibiotics   J01* 
Psycholeptics   N05* 
Antidepressants   N06A* 
SSRI   N06AB* 
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Table 3A: Genetic and teratogenic syndromes diagnosed in Ebstein’s Anomaly cases 
who were excluded from the case malformed control study. 
Case  Diagnosis Karyotype 
1 Additional marker autosomes Unknown 
2 Other loss of autosomal material Unknown 
3 Down syndrome 47,XY,+21 
4 Down syndrome Unknown 
5 Turner syndrome Unknown 
6 Partial trisomy 46,XY,der(20)t(2;20) 
6 Down syndrome 47, XY, +21  
8 Down syndrome Unknown 
9 Down syndrome 47, XX + 21 
10 Down syndrome 47,XX,+21 
11 Down syndrome 47,XX+21 
12 Prader-Willi syndrome unknown 
13 Pena Shokeir syndrome unknown 
14 Maternal cytomegalovirus - 
 
 
 
Table 3A: Number of Ebstein’s anomaly cases with relevant family history 
Family History No. of EA cases Remarks 
Co-twin with EA 2 (I twin pair) Twin to twin transfusion 
EA 1 Cousin (not in our data) 
Pena Shokeir 
syndrome 
1 (case 13) Sibling without EA 
Congenital Cardiac 
anomaly 
2 First degree relatives 
Congenital Cardiac 
anomaly 
9 Second degree relatives 
Chromosomal 
anomaly 
1 Co-twin without EA 
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Table 5A 
 
Table 5A: Non-CHD congenital anomalies seen in non-syndromic Ebstein’s anomaly 
cases 
Congenital anomaly Multiple 
anomalies*, 
no. and (%) 
of EA cases 
Multiple 
anomalies*, no. 
and (%) of non- 
EA CHD cases 
Any non-CHD anomaly 22(8.8) 6326 (18) 
Eye 3 (1.2) 347 (1.0) 
Nervous system 4 (1.6) 1,113 (3.1) 
  Hydrocephalus 1 (0.4) 299 (0.8) 
  Microcephaly 1 (0.4) 215 (0.6) 
Oro-facial clefts 3 (1.2) 593 (1.7) 
  Cleft lip with or without palate 2 (0.8) 323 (0.9) 
  Cleft palate 1 (0.4) 270 (0.8) 
Ear face and neck 3 (0.8) 326 (0.9) 
Respiratory 3 (1.2) 613 (1.1) 
Digestive system 6 (2.4) 1,360 (3.8) 
  Diaphragmatic hernia 2 (0.8) 189 ((0.5) 
Urinary 4 (1.2) 1,345 (3.8) 
  Congenital hydronephrosis 2 (0.8) 329 (0.9) 
Genital 3 (1.2) 593 (1.7) 
  hypospadias 2 (0.8) 397 (1.1) 
Limb 3 (1.2) 1,383 (3.9) 
  Hip dislocation (non-isolated) 1 (0.4) 157 (0.4) 
  Polydactyly 2 (0.8) 243 (0.7) 
  Syndactyly 1 (0.4) 161 (0.5) 
Craniosynostosis 1 (0.4) 70 (0.2) 
NB Ebstein’s anomaly cases may appear more than once in this table if they have more than one other major congenital anomaly 
 
Table 6A: Ebstein’s anomaly: Prevalence per 10,000 total births over time and by 
country 1982-2011 
Country n 1982-1991 n 1992-2001 n 2002-2011 n 1982-2011 
Denmark 4 0.81 (0.30-2.15) 5 0.86 (0.36-2.07) 1 0.19 (0.03-1.36) 10 0.63 (0.34-1.16) 
France 9 0.25 (0.13-0.47) 24 0.66 (0.45-0.99) 28 1.05 (0.72-1.52) 61 0.61 (0.48-0.79) 
Netherlands 6 0.48 (0.22-1.07) 9 0.46 (0.24-0.88) 11 0.60 (0.33-1.07) 26 0.51 (0.35-0.75) 
Switzerland 3 1.30 (0.42-4.02) 6 0.79 (0.35-1.75) 4 0.53 (0.20-1.42) 13 0.75 (0.43-1.29) 
Malta 2 0.62 (0.15-2.46) 4 0.85 (0.32-2.26) 5 1.39 (0.58-3.34) 11 0.95 (0.53-1.72) 
Belgium 1 1.19 (0.17-8.42) 5 0.37 (0.15-0.88) 6 0.30 (0.14-0.68) 12 0.35 (0.20-0.62) 
Germany 0 0 3 0.28 (0.09-0.87) 9 0.52 (0.27-1.00) 12 0.34 (0.19-0.60) 
Ukraine  -  - 13 0.62 (0.36-1.07) 13 0.62 (0.36-1.07) 
Ireland  - 4 0.53 (0.20-1.42) 7 0.44 (0.21-0.93) 11 0.47 (0.26-0.85) 
Italy 3 0.10 (0.03-0.29) 22 0.43 (0.29-0.66) 15 0.22 (0.13-0.37) 40 0.27 (0.20-0.36) 
Wales   11 0.86 (0.48-1.55) 21 0.62(0.40-0.95) 32 0.69 (0.49-0.97) 
Spain 1 0.31 (0.04-2.17) 10 0.61 (0.33-1.14) 12 0.30 (0.17-0.53) 23 0.39 (0.26-0.58) 
Total 29 0.29 (0.20-0.41) 103 0.55 (0.46-0.67) 132 0.48 (0.40-0.57) 264 0.47 (0.41-0.53) 
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Figure 1A: Flowchart showing data used in each exclusions and numbers included in each group of 
analyses 
 
 
 
 
 
Population 
5,644,312 births 
144,820 
Babies/fetuses with other 
congenital anomalies 
Controls 
264  
Babies/fetuses with 
Ebstein’s anomaly 
Cases 
145,084 
babies/fetuses 
with of major 
congenital 
 
 
Used in the prevalence analyses 
Controls excluded 
20,316 chromosomal, 2,898 
genetic, 649 skeletal dysplasia, 
677 teratogenic syndrome, 5,698 
congenital hip dysplasia and 
35,904 other cardiac anomalies 
Cases excluded 
11 chromosomal, 2 genetic 
and 1 teratogenic syndrome 
   
 
 
35,904 cardiac 
controls 
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malformed-control analyses 
 
51,024  non 
cardiac 
controls 
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37,388 
 
Cases with no 
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cardiac 
controls 
26,170 cardiac 
controls 
